- Design
- Sequence-symmetry analysis with active comparator plus VigiBase disproportionality
- Population
- 36,163 PCSK9 inhibitor and 34,269 ezetimibe initiators, France 2018–2023
- Primary outcome
- Potential safety signals across 700 outcomes
- Effect
- Two signals: inhaled steroids SRa 1.19 (1.06–1.35); CSFs SRa 2.25 (1.37–4.17)
A pharmacovigilance study in Drug Safety (22 September) screened 700 outcomes in 36,163 people starting PCSK9 inhibitors in the French national health database, compared with 34,269 starting ezetimibe to control for indication. It used sequence-symmetry analysis — whether a new drug or event appears more often after starting the PCSK9 inhibitor than before — and cross-checked against the WHO VigiBase database.
Only two potential signals emerged: new inhaled corticosteroid prescriptions (adjusted sequence ratio 1.19, 95% CI 1.06–1.35) and colony-stimulating factors (2.25, 1.37–4.17). Neither was reflected in VigiBase, and the authors attribute both to residual confounding.
For prescribers, this supports the reassuring safety profile seen in the outcome trials, now in over 36,000 real-world users. Injection-site reactions remain the main practical issue.
- Counsel on injection technique and site reactions
- No new routine monitoring is suggested by these data
- Continue to report unexpected events to the national pharmacovigilance programme
- In India, cost rather than safety is usually the barrier to use
Why it matters
It adds real-world reassurance for a drug class often held back over unfamiliarity.
Don't overread it
Signal detection studies can miss rare or delayed harms and are not designed to confirm safety.
The statistics, in plain English
A sequence ratio above 1 means the event more often follows starting the drug than precedes it. Screening 700 outcomes will throw up a few chance or confounded signals; finding only two weak ones, unconfirmed elsewhere, is reassuring.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free